Dr. Epner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
500 University Dr
Hershey, PA 17033Phone+1 800-233-4082Fax+1 808-442-5112
Education & Training
- University of WashingtonFellow, Molecular Oncology, 1988 - 1991
- University of WashingtonFellowship, Hematology and Medical Oncology, 1986 - 1989
- University of California (Irvine)Residency, Internal Medicine, 1984 - 1986
- Columbia UniversityPhD, Human Genetics, 1983 - 1985
- University of California (Irvine)Internship, Internal Medicine, 1983 - 1984
- Columbia University Vagelos College of Physicians and SurgeonsClass of 1983
- Wesleyan UniversityBA, Biology, 1972 - 1976
Certifications & Licensure
- OR State Medical License 2003 - Present
- MD State Medical License 2021 - 2026
- PA State Medical License 2008 - 2024
- VA State Medical License 2016 - 2024
- DE State Medical License 2022 - 2023
- ME State Medical License 2016 - 2022
- CA State Medical License 2016 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- Grants Awarded International Myeloma Foundation 2001, 2002, 2010
- Grants Awarded National Institutes of Health, 2004
- Mentor, AACR Young Investigator Scholar Award, 2000 2003
- Join now to see all
Clinical Trials
- S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma Start of enrollment: 2002 Sep 01
- Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
- Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma Start of enrollment: 2008 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 39 citationsEpigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemiaZainul Hasanali, Bikramajit Singh Saroya, August Stuart, Sara Shimko, Juanita J. Evans
Science Translational Medicine. 2015-06-24 - 101 citationsA phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213Steven H. Bernstein, Elliot M. Epner, Joseph M. Unger, Michael LeBlanc, Erin Cebula
Annals of Oncology. 2013-06-01 - 261 citationsBortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE studyAndre Goy, Steven H. Bernstein, Brad S. Kahl, Benjamin Djulbegovic, Michael J. Robertson
Annals of Oncology. 2008-01-01
Journal Articles
- The Beta-Globin LCR is not Required for an Open Chromatin Structure or Low Level Transcription of the Mouse Beta-Globin Locus.Epner,E, Reik, A, Cimbora, D, Telling, A, Fiering, S, Keller, G, and Groudine, M, Molecular Cell
- The locus control region is necessary for beta-globin gene expression but not for the maintenance of an open chromatin structure in erythroid cells.Reik, A, Telling, A, Zitnik, G, Epner, E and Groudine, M, Mol. Cell Biol
- A Multicenter Phase II Study of Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma.Fisher,R, Bernstein S, Kahl, B, Djulbegovic, B, Robertson M, De Vos S, Epner, E, Krishnan A, Leonard J, Lonial S, Stadtmauer E, Oconnor O, Shi, H, Boral A, and Goy A, Journal of Clinical Oncology
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).Andres Forero-Torres, Steven H. Bernstein, Ajay Gopal, Francine Foss, John P. Leonard, Joseph D. Rosenblatt, Nancy L. Bartlett, Bruce D. Cheson, Elliot Epner, Francisc..., Blood American Society of Hematology Annual Meeting
- Desferroxamine: An anti-cyclin D1 agent cytotoxic against cyclin D1 (+) mantle cell lymphoma and multiple myeloma cell lines.Epner, E, American Association of Cancer Research
- Long Distance Trans DNA Hypomethylation in Cyclin D1 Deregulated B Cell Malignancies.Hui Liu, Jin Wang, Jing Huang, and Elliot M. Epner, Blood American Society of Hematology Annual Meeting
- Join now to see all
Lectures
- Traumatic Brain Injury.University of CA, Irvine Department
- Rehabilitation Issues in Parkinson’s Disease.Huntington Parkinson’s Support Group
- Bladder Function and Dysfunction.Casa Colina Centers for Rehabilitation Stroke Symposium
- Join now to see all
Other
- Recombination-proficient avian/mammalian microcell hybrids.Epner E
- Targeting nucleophosmin in mantle cell lymphoma.Epner E
- Therapeutic drug combinations for the treatment of B Cell Malignancies.Epner E
- Join now to see all
Press Mentions
- Oncotarget | Combined Epigenetic and ImmunothAugust 16th, 2022
- Iron Chelation and 2‐Oxoglutarate‐Dependent Dioxygenase Inhibition Suppress Mantle Cell Lymphoma's Cyclin D1September 13th, 2019
Grant Support
- Genetic Analysis Of The Chicken Beta-Globin LocusNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2004
- Genetic Analysis Of The Chicken Beta-Globin LocusNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2002
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: